Jiangsu Kanion Pharmaceutical announced that the company recently received the "Drug Clinical Trial Approval Notification" for KYS0.202 million A injection issued by the National Medical Products Administration, allowing the clinical trial for advanced solid tumors to commence. KYS0.202 million A injection is a self-developed oncolytic virus product that mainly selectively infects tumor cells, inducing the formation of syncytia and the lysis of tumor cells, while activating anti-tumor immune responses. Preclinical studies have shown that this pharmaceutical can specifically target various tumor cells and has good safety and tolerability. Currently, the company has invested about 70.3 million yuan in the development of this new drug. The product's market launch still requires the completion of phase I-III clinical trials and the fulfillment of relevant approval procedures.